nuous evaluation of anti-HIV regimens. There is need therefore, for regular surveillance and monitoring for mutations that are likely to lead to drug resistance if we have to achieve successful treatment outcomes.
Introduction
Human Immunodeficiency Virus (HIV) infection is today one of the most devastating infections globally. Ever since the discovery of the virus some two decades ago, there has been a dramatic increase in infections and deaths due to this virus.
HIV is a member of the retroviridae family, which has a single stranded RNA genome. Two major types of HIV are currently recognised: HIV type 1 (HIV-1), and HIV type 2 (HIV-2). HIV-1 is further divided into three genetic groups: group M (major or main), group O (outlier) and group N (new or non-M, non-N) [1] . While groups O and N are restricted to countries of Central Africa, notably Cameroon; HIV-1 group M is widely distributed worldwide. It is responsible for the AIDS pandemic, which accounts for over 90% of HIV infections [2] . HIV-2 is restricted to countries in West Africa, where it also represents a minority of viral infections (3% of total HIV infections). Fortunately, it is decreasing in prevalence over time [3] .
Molecular Epidemiology of HIV
HIV-1 subtype diversity is the highest in the world. Over nine pure subtypes of HIV-1 group M are currently known (A-D, F-H, J and K). Some of these subtypes are further subdivided into sub-subtypes e.g. subtypes F (F1 and F2); A (A1, A2 and A3). Intrasubtype divergence of up to 20% also occurs. Furthermore, intersubtype divergence of about 25% to 35% occurs, for the env amino acid sequences [1] [4] [5] . This intermixture of HIV-1 variants that circulate together within a geographical region provides an opportunity for recombination of virus strains within dually or multiply infected individuals [6] . Some of these recombinant forms may further achieve epidemic relevance, giving rise to unknown circulating recombinant forms (CRFs) thus complicating therapy. To date, over 40 CRFs are recognized in diverse parts of the world [7] . It is currently believed that HIV-1 M subtypes and CRFs are the result of founder effects in different geographic locales, followed by localised evolution. As a consequence, such HIV-1 forms are heterogeneously spread out worldwide [2] .
Distribution of HIV-1 Subtypes
Africa has all HIV-1 subtypes, although A and C predominate [8] . In East Africa, subtypes A and D have dominated Uganda from mid 1980s [9] . These subtypes A and D have also been isolated from various parts of Tanzania [10] . However, in the Southern Tanzania town of Mbeya, the predominant subtype is C [11] . This is believed to have been introduced from Southern African countries where subtype C is predominant [12] .
HIV-1 epidemic in Kenya like the rest of the world shows regional heterogeneity. On the basis of the env C2-V3, Neilson et al., 1999 ; found that subtype A predominates (71% -87%), with significant components of subtype D (7% -29%) and subtype C (7% -17%). Carr et al., 2005 [14] has identified a full-length subtype G in Kenya. On the other hand, it has been established that HIV-1 subtypes circulating in the Northern Kenya town of Moyale mainly comprise subtype A (50%), subtype C (39%) and subtype D (11%); i.e. subtypes A and C are predominant. This is probably influenced by neighbouring Ethiopia which is dominated by HIV-1 subtype C. It has been suggested that this scenario is indicative of cross-border movements influencing circulation of subtypes in northern Kenya [13] . Evidence of increasing HIV-1 diversity is emerging. For example, Lihana et al., 2006 [15] identified four circulating recombinant forms: between A1, A2, and D; A2 and D; A1 and D; A1 and G; A1 and C; A1, C and D have been documented among STI patients in Nairobi.
In the context of this increasing HIV-1 subtype diversity, it requires further studies in other parts of Kenya to monitor for mutations that are likely to lead to drug resistance if we have to achieve successful treatment out-comes. Thus, this study was conducted in western Kenya bordering Uganda.
Materials and Methods

Study Site
The study was conducted in western Kenya at sites within the border area of Kenya and Uganda. The five sites: Butula, Busia, Budalangi, Funyula and Mumias were selected to reflect representative number of patients in the cohort. This region has an adult HIV prevalence of 6.7% (NASCOP 2007).
Study Population and Sampling
The study covered a cohort of 1000 patients on antiretroviral therapy supported by the Medecins Sans Frontieres (MSF) programs in Busia district hospital between 2007 and 2009. From this cohort, 75 persons were randomly selected. The samples analysed come from persons resident in the rural villages ( Table 1 ) who, since they tend to travel less often, were very likely to have acquired their HIV infection in their villages. This facility serves patients from both Kenya and Uganda. Inclusion criteria comprised having been enrolled on antiretroviral therapy for at least 6 months.
Blood Samples
After obtaining informed consent, venous blood collection was performed according to the protocol previously approved by the Kenya Medical Research Institute Scientific Steering Committee and Ethical Review Board (Ref. KEMRI SSC No. 1127). At least 5ml of whole blood were collected into vacutainer tubes from each study subject. The blood was packed and transported to the HIV lab in Nairobi for further analysis.
DNA Extraction
Peripheral blood mononuclear cells (PBMCs) were extracted from whole blood by density gradient centrifugation using Ficoll-Paque Plus (Pharmacia) and DNA extracted using DNAzol (Gibco BRL ® ) and ethanol precipitation. The extracted proviral DNA was used for polymerase chain reaction (PCR) amplification. A region of the HIV-1 protease gene was amplified by nested PCR. Primers NYUPOL7 (5'-GGGAATTTTCTTCAGAGCAG-3'), and NYUPOL8 (5'-TCTTCTGTCAATGGCCATTGT-3') were used in the first round and primers NYUPOL9 (5'-TCCTTAACTTCCCTCAAATCACT-3') and NYUPOL10 (5'-CTGGCACGGTTTCAATAGGACT-3') were used in the second round to amplify 297 bp of the protease gene region corresponding to positions 2513 -3209 in HIV-1 HXB2 sequence. The first round PCR was carried out in 25.0 µl tube containing 2.0 μl of DNA, 2.0 μl of 10× buffer, 0.4 μl of each forward and reverse primers (NYUPOL7 and NYUPOL8), 2.8 μl MgCl 2 , 10.2 μl of distilled water and 0.2 μl of Taq polymerase. The amplification was carried out in a thermal cycler (MJ Research, Inc). Amplification was carried out with 1 cycle of 95˚C for 10 min and 35 cycles of 95˚C for 30 s, 30˚C for 60 s, and 72˚C for 1 min, and final extension of 72˚C for 10 min. The nested PCR used 2.0 μl of the first round PCR products as a template and used inner primers (NYUPOL9 and NYUPOL10) with the same cycling conditions. The PCR amplification was confirmed by ethidium bromide staining of samples electrophoresed on a 1.5% agarose gel.
Sequencing and Phylogenetic Analysis
The primers NYUPOL9 were used for PCR direct sequencing in an automated DNA sequencer (ABI 3100 Applied Biosystems, Foster City, CA) with BigDye Terminator version 3.0 Cycle Sequencing Reaction Kits (Applied Biosystems, Foster City, CA). The sequences were then aligned with previously reported HIV-1 strains of various subtypes from the Los Alamos HIV-1 database (http://hiv-web.lanl.gov) using CLUSTAL W profile alignment option. After sequencing the 75 samples, the generated nucleotides were analysed by BLAST to determine the HIV subtypes.
Genetic distances were calculated by the two-parameter method of Kumar et al., 2001 [16] . On this basis, only 64 samples were used to construct the phylogenetic tree by neighbour-joining method since the other sequences were too short (tree not shown). The reliability of the tree was estimated by 1000 bootstraps [16] [17] . The tree profile was visualized with Tree View PPC version 1.6.5. The generated sequences were deposited in the Genbank with accession numbers HQ176975-HQ177040.
Results
The most predominant HIV-1 subtype in this region was A1 (52%) followed by subtype D (28%) both of which are associated with Uganda. Increased HIV-1 genetic diversity is evident as shown by the six genetic subtypes (A1, D, G, C, A2, B) and two intersubtype recombinants (A1/C, and A1/D) identified (Figure 1) . The majority of the HIV-1 subtypes from this study appear to be restricted to those commonly circulating in East Africa. For instance, a total of 35 isolates from this study resembled those previously reported from Uganda in the Genbank, while 23 isolates resembled those from Kenya and only 5 isolates resembled those from Tanzania.
Discussion
In Kenya, the majority of circulating strains belong to HIV-1 group M. However, there seems to be a lot of variation, which appears to be influenced by neighbour countries. For example, Neilson et al., 1999 [18] has shown that countrywide subtype A predominates (71% -87%), with significant components of subtype D (7% -29%) and subtype C (7% -17%). Carr et al., 2005 [14] only identified subtype G. This scenario is different from that obtaining in the Northern region of Kenya town of Moyale bordering Ethiopia where on the basis of partial env sequences, Khamadi et al., 2005 [13] reported that subtype A (50%), subtype C (39%) and subtype D (11%) were dominant. He attributed this to the fact that Kenya and Ethiopia share a long common border, resulting in a lot of cross-border migration, due to trade and tourist activities which may be responsible for the dynamic introduction of differing HIV subtypes and circulating recombinant forms. It must be noted that Ethiopia is dominated by HIV-1 subtype C, which interestingly is also among the dominant subtypes in Northern Kenya. Lihana et al., 2006 [15] appears to have observed a lot of HIV-1 subtype recombinations among STI patients in Nairobi. He documented that Subtype C and D occur as non-recombinants but to a much lesser extent than subtype A. it is possible that because Nairobi is cosmopolitan, there may exist dually or multiply infected individuals which enhances opportunity for HIV-1 recombinations. These recombinations appear to be occurring recombinants between A1, A2, and D; A2 and D; A1 and D; A1 and G; A1 and C; A1, C and D.
Our study seems to support the observation that HIV-1 diversity in the border regions could be as broad as that reported in major cities. For instance, like other parts of the country the predominant circulating subtype in western Kenya is A1. However, border country influence seems to be in play in that in the Kenya-Uganda border subtype D is predominant, which is also the most dominant subtype in Uganda. Similarly in Moyale (KenyaEthiopia border) subtype C is rampant probably due to influence from Ethiopia where subtype C is dominant. Like Lihana et al., 2006 [15] reported, some HIV-1 subtype recombinations were also observed in this study. These were A1C and A1D.
It is well known that there is a lot of HIV-1 subtype diversity in the world, albeit with a degree of regional segregation. Africa has all HIV-1 subtypes but A and C predominate [8] . However, in East Africa, not withstanding the continental predominance of subtypes A, there is also a significant presence of subtype D [9] . To underline the phenomenon of segregation, our study area showed subtypes A1 and D being the most common. The few pockets of subtypes G and C observed could be due to the rampant human travels and migration patterns that may lead to introduction of other HIV-1 subtypes. For example the presence of subtype G and C in our study area at the Kenya-Uganda border could probably be due to the fact that this study area is a gateway to Central Africa, notably the Congo where subtype C is predominant. The phenomenon of border country influence could further be supported by phylogenetic similarities of the sequenced viruses and those they were compared to from the Genbank. There was little evidence of HIV-1 subtype B in circulation which is the predominant virus circulating in Europe, and is also found in Indonesia, the Philippines, and Taiwan [19] , which countries are far removed from Kenya.
Conclusion
Findings from this study reveal the complexity of HIV-1 infection in the Kenya-Uganda border region similar to those documented by Khamadi et al., 2005 [13] at the Kenya-Ethiopia border. There are continuous HIV-1 recombinations. These could portend future global pandemics, which may be characterised by even more genetically diverse viruses. There is therefore, a need for continuous review of control and treatment programs especially in the border regions. For example, surveillance studies on the extent of inter-subtype recombinations are necessary for continuous improvement of diagnosis, treatment or vaccine development. To understand further the epidemiology of HIV-1 subtype diversity in border areas, analysis of human travels, migration patterns as well as social conditions need to be done, if therapeutic interventions have to be successful.
